About Killer cell immunoglobulin-like receptor 2DL2
Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) is a protein
from Homo sapiens identified by UniProt accession
P43627, 348 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Killer cell immunoglobulin-like receptor 2DL2 |
|---|
| UniProt accession | P43627 |
|---|
| Gene | KIR2DL2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 348 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (10)
Diseases linked to this target (Open Targets).
- multiple myeloma · score 0.10
- acute myeloid leukemia · score 0.10
- head and neck squamous cell carcinoma · score 0.07
- chronic lymphocytic leukemia · score 0.07
- leukemia · score 0.07
- cancer · score 0.05
- neoplasm · score 0.04
- non-Hodgkins lymphoma · score 0.04
- urinary bladder cancer · score 0.04
- Hodgkins lymphoma · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P43627-F1 | alphafold | PREDICTED | 74.95 | — |
Amino-acid sequence (348 residues)
MSLMVVSMAC VGFFLLQGAW PHEGVHRKPS LLAHPGRLVK SEETVILQCW SDVRFEHFLL HREGKFKDTL HLIGEHHDGV SKANFSIGPM MQDLAGTYRC YGSVTHSPYQ LSAPSDPLDI VITGLYEKPS LSAQPGPTVL AGESVTLSCS SRSSYDMYHL SREGEAHECR FSAGPKVNGT FQADFPLGPA THGGTYRCFG SFRDSPYEWS NSSDPLLVSV IGNPSNSWPS PTEPSSKTGN PRHLHILIGT SVVIILFILL FFLLHRWCSN KKNAAVMDQE SAGNRTANSE DSDEQDPQEV TYTQLNHCVF TQRKITRPSQ RPKTPPTDII VYAELPNAES RSKVVSCP
Explore Killer cell immunoglobulin-like receptor 2DL2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets